Xeloda Adjuvant Colon Cancer sNDA Supports New Standard Of Care – Roche
Roche's sNDA for use of Xeloda as adjuvant therapy for colon cancer supports use of the oncologic as a new standard of care for the indication, the company maintained
Roche's sNDA for use of Xeloda as adjuvant therapy for colon cancer supports use of the oncologic as a new standard of care for the indication, the company maintained